Invesaro

Stocks Health care PALI

NASDAQ · Health care

Palisade Bio, Inc. (PALI)

Palisade Bio, Inc. brought in $500K of revenue over the twelve months to June 30, 2026. It posted a net loss of $31.9M. At June 30, 2026 it held $125.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.

Price
$1.45
-7.64% on the day · September 25, 2026
52-week range $0.81 to $2.86
Market cap
$252.7M
Revenue (last 12 months)
$500K
Net margin
-6,388.2%

What Palisade Bio, Inc. does

Palisade Bio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker PALI.

Revenue and profit by year

Revenue
FY18: $260K $260K FY18FY19: $15.4K $15.4K FY19FY20: $13.5K $13.5K FY20FY22: $0 $0 FY22FY23: $300K $300K FY23FY24: $0 $0 FY24FY25: $0 $0 FY25
Net income
FY18: -$4.9M -$4.9M FY18FY19: -$8.4M -$8.4M FY19FY20: -$10.3M -$10.3M FY20FY21: -$26.6M -$26.6M FY21FY22: -$14.3M -$14.3M FY22FY23: -$12.3M -$12.3M FY23FY24: -$14.4M -$14.4M FY24FY25: -$16.8M -$16.8M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$0-$18.1M-$16.8M-$0.30n/a
2024$0-$14.9M-$14.4M-$10.19-$12.2M
2023$300K-$13.1M-$12.3M-$27.01-$11.1M
2022$0-$15.7M-$14.3M-$248.04-$13.4M
2021n/a-$41.9M-$26.6M-$2,547.04-$14.8M
2020$13.5K-$9.3M-$10.3M-$2,794.99-$4.8M

Latest SEC filings

What Palisade Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 14, 2026
  2. August 13, 2026
  3. August 10, 2026
  4. August 10, 2026
    Quarterly report 10-Q · period to June 30, 2026
  5. July 29, 2026
  6. June 11, 2026
  7. June 10, 2026
  8. May 27, 2026
  9. May 15, 2026
  10. May 15, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 21, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about PALI

What does Palisade Bio, Inc. do?

Palisade Bio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker PALI.

Is Palisade Bio, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $31.9M on revenue of $500K.

How much revenue does Palisade Bio, Inc. make?

Over the twelve months to June 30, 2026 Palisade Bio, Inc. reported revenue of $500K.

When did Palisade Bio, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 21, 2026.

Similar companies

Follow PALI

Get an email when Palisade Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow PALI: get an email when it files

Where the numbers come from

Financial figures are the values Palisade Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.